drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
An antibody-drug conjugate linking the anti-HER2 monoclonal antibody trastuzumab to the maytansinoid cytotoxin DM1, delivering DM1 to HER2-overexpressing tumor cells after receptor-mediated internalization; inhibits HER2 signaling and mediates ADCC while the released DM1 disrupts microtubules causing mitotic arrest and cell death.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Ado-Trastuzumab Emtansine
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
HER2-directed monoclonal antibody trastuzumab linked to the maytansinoid DM1. Trastuzumab binds HER2, inhibiting HER2 signaling and mediating ADCC; after receptor-mediated internalization, DM1 is released to disrupt microtubules, causing mitotic arrest and tumor cell death.
drug_name
ado-trastuzumab emtansine (T-DM1)
nct_id_drug_ref
NCT05889988